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Abstract: Myocardial infarction (MI) leads to the loss of cardiomyocytes, left ventricle 
(LV) dilation, and cardiac dysfunction, eventually developing into heart failure. Most 
of the strategies for MI therapy require biomaterials that can support tissue regeneration. 
In this study, we hypothesized that the extracellular matrix (ECM)-derived collagen I 
hydrogel loaded with histone deacetylase 7 (HDAC7)-derived-phosphorylated 7-
amino-acid peptide (7Ap) could restrain LV remodeling and improve cardiac function 
after MI. An MI model was established by ligation of the left anterior descending (LAD) 
coronary artery of C57/B6 mice. The 7Ap-loaded collagen I hydrogel was 
intramyocardially injected to the infarcted region of the LV wall of the heart. After local 
delivery, the 7Ap-collagen increased neo-microvessel formation, enhanced Sca-1+ stem 
cell recruitment and differentiation, decreased cellular apoptosis, and promoted 
cardiomyocyte cycle progression. Furthermore, the 7Ap-collagen restricted the fibrosis 
of the LV wall, reduced the infarct wall thinning, and improved cardiac performance 
significantly at 2 weeks post-MI. These results highlight the promising implication of 
7Ap-collagen as a novel candidate for MI therapy. 
 
Keywords: myocardial infarction; collagen I hydrogel; 7Ap peptide; angiogenesis; 
anti-apoptosis; stem cell recruitment; cardiac functional recovery. 
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1. Introduction 
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MI is an irreversible myocardium injury due to severe and accentuated reduction in 
coronary perfusion, making it one of the most serious ischemic heart diseases 
worldwide [1]. MI causes left ventricle (LV) remodeling, including progressive 
extracellular matrix (ECM) degradation, LV wall thickness increase, scar formation, 
and finally transition to heart failure in the late phase [2]. Currently, surgical 
intervention, such as bypass and stenting operation, is the first choice for MI patients. 
Because the surgery can only attenuate the symptoms, the regeneration of infarct tissue 
is less effective [3].  
Various bio-activate molecules, such as growth factors, functional peptides, and 
stem cells have been widely applied for ischemic heart regeneration [4-6]. Histone 
deacetylases (HDACs) are a family of enzymes that remove acetyl groups from N-
acetylated lysine residues on histones and HDACs play an important role in promoting 
chromatin compaction and modulating gene transcription, hence regulating many 
aspects of cardiovascular diseases, including MI from pathogenesis to therapeutics [7-
9]. HDAC7 belongs to the class II HDAC family, and is specifically expressed in the 
vascular endothelium and contributes to the maintenance of vascular integrity during 
early embryogenesis [10, 11]. There are several splicing variants in HDAC7 mRNAs. 
One of the mouse Hdac7 transcript variants has a short open reading frame (sORF) 
located in the 5’ terminal non coding area, encoding a 7-amino-acid peptide (7A, 
MHSPGAD). The 7A could transfer the phosphate group from the phosphorylated 
Ser393 site of MEKK1 to the site of 14-3-3γprotein, forming an MEKK1-7A-14-3-
3γsignaling pathway. The phosphorylated 7A (7Ap, MH[pSer]PGAD) was shown to 
increase stem cell migration, proliferation, and differentiation, especially that of 
vascular progenitor cells (VPCs). 7Ap enhanced angiogenesis, ameliorated vascular 
injury and promoted blood perfusion recovery in in a femoral artery injury model and 
a hindlimb ischaemia model [12]. According to the properties of 7Ap, in this study, we 
speculated that the peptide should greatly contribute to MI therapy. 
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Despite the ongoing research activities conferred on peptides, several central 
concerns should be addressed. For instance, peptides exhibit short half-life and can be 
easily degraded by endogenous peptidases, whereas tissue engineering has provided a 
choice to overcome these shortcomings. Currently, various bio-active elements 
combined with biomaterials have been applied for ischemic heart regeneration, and 
these biomaterials are often fabricated into injectable forms [4, 13]. Hydrogel, one kind 
of injectable biomaterial, has the advantages of minimizing invasion, maintaining 
cardiac structure, and acting as vehicles to deliver bio-active elements in situ [14, 15]. 
Numerous natural biomaterials have been used for cardiac tissue engineering such as 
collagen, gelatin, laminin, chitosan and hyaluronic acid [16]. Collagen I is one kind of 
ECM proteins and it can assemble into a 3D polymeric network with a high-water 
content. Collagen I based hydrogel has been used extensively as scaffolds for tissue 
engineering or as delivery systems for stem cells and/or therapeutic agents, because it 
can provide a favorable microenvironment for cell survival and proliferation. Moreover, 
it constitutes a functional platform to prolong the retention of the bio-active elements 
[17, 18]. Owing to its high permeability and biocompatibility, Injectable collagen I 
hydrogel has already been applied for MI therapy in animal models [19, 20].  
The aim of this study was to develop a 7Ap-loaded collagen I hydrogel that provides 
a conducive environment for cardiac tissue repair and regeneration. Locally released 
7Ap from the collagen hydrogel serves as a bioactive factor with anti-apoptotic and 
angiogenic function; it could further promote the mobilization and recruitment of 
endogenous Sca-1+ stem cell to the site of injury. Collectively, intra-myocardial 
delivery of 7Ap-loaded collagen will enhance the revascularization around the site of 
injury and contribute to MI therapy. 
 
2. Materials and Methods 
2.1 Preparation of peptides and hydrogels 
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The 7Ap peptide was synthesized by Genscript (Piscataway, USA). The preparation 
of collagen I hydrogel was reported previously [14]. Briefly, highly hydrated collagen 
was produced by adding 1.1 ml of saline to 0.9 ml of sterile rat tail collagen type I (BD 
Biosciences, USA) in acetic acid (3.84 mg/ml, Millipore, US). The resulting 2-ml 
collagen/saline mixture was mixed well, and the final pH was adjusted to 7.4 using 0.1 
M of NaOH. The 7Ap-collagen was prepared by mixing peptide stock solution with 
collagen at 4°C. The final concentrations for 7Ap and collagen I were 0.1 μg/kg and 
3.3 mg/ml, respectively. For animal experiments, 20 μl of the 7Ap- collagen was 
injected into the myocardium of the infarcted heart. The collagen-based hydrogel was 
liquid at the time of intra-myocardial injection but shows gelation at physiological 
temperature (37°C) within 10 minutes.  
2.2 Characterization of 7Ap-loaded collagen hydrogel 
(a) The morphology of 7Ap-loaded collagen hydrogel 
After lyophilization, the 7Ap-collagen was examined using scanning electron 
microscopy (Quanta 200; FEI, Brno). Briefly, the freeze dried hydrogel was first cut to 
display their inner structures. After spraying a gold layer, the cross sections were 
visually observed by SEM.  
(b) In vitro release of 7Ap 
Hydrogel with 200mg of fluorescein isothiocyanate (FITC)-conjugated 7Ap (7Ap-
FITC) (n=3) was incubated in 1 ml of phosphate-buffered saline (PBS) at 37°C. At each 
time point, supernatants were collected and stored at 4°C for analysis, followed by the 
addition of 1 ml of fresh PBS. The amount of 7Ap-FITC in the supernatant was 
measured by fluorescence intensity at 490 nm using a PerkinElmer EnSpire 
(PerkinElmer LLC). A standard curve was carried out using a series of known 7Ap-
FITC contents in PBS solution. All experiments were replicated 3 times. 
 
2.3 H9C2 cell culture under hypoxia/serum deprivation (H/SD) conditions 
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The rat heart tissue-derived H9C2 cardiac myoblast cell line was purchased from 
American Type Culture Collection (ATCC, USA) and maintained in Dulbecco's 
modified Eagle's medium (DMEM) (Invitrogen, USA) supplemented with 10% fetal 
bovine serum (FBS) (Invitrogen, USA) and 100 U penicillin/streptomycin at 37°C in a 
humidified 5% CO2–95% O2 incubator. To induce ischemia, cells cultured in a 
simulated ischemia solution (glucose-free Tyrode solution containing 10 mM2-deoxy-
D-glucose and 10 mM of sodium dithionite) were exposed to hypoxia (<1% O2) by 
placing the plates in a hypoxia chamber for 2 h.  
To test the effect of 7Ap on cardiac ischemia injury in vitro, H9C2 were seeded in 6-
well plates at a density of 5 × 104 cells per well 24 h prior to the experiment. The cells 
were assigned to 3 groups randomly as follows: normal group (cells were cultured in 
DMEM+10% FBS, in a 95% O2 atmosphere) n=5; H/SD group (cells were cultured in 
simulated ischemia solution, in a 1% O2 atmosphere), n=5; and 7Ap + H/SD group 
(cells were exposed to 1 ng/ml 7Ap and cultured in simulated ischemia solution, in a 
1% O2 atmosphere), n=5. After 2 hours, cells in each group were harvested and prepared 
for fluorescence-activated cell sorting (FACS) and western blot experiments.  
2.4 FACS examination  
Cells were harvested after the incubation period and washed in cold PBS. The cells 
were stained with Annexin V (Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit, 
BD, US) according to the protocol provided. Finally, the numbers of Annexin V-
positive cells were examined by FACS (Calibur, USA). Normal group (positive control) 
(cells were cultured in DMEM+10% FBS, in a 95% O2 atmosphere) n=5; H/SD group 
(negative control) (cells were cultured in simulated ischemia solution, in a 1% O2 
atmosphere), n=5; and 7Ap + H/SD group (cells were exposed to 1 ng/mL 7Ap and 
cultured in simulated ischemia solution, in a 1% O2 atmosphere), n=5. All experiments 
were replicated 3 times. 
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2.5 Western blot analysis 
Whole cell lysates were prepared with protein concentrations measured by Bio-Rad 
reagents (Hercules, USA). Fifty micrograms of cell lysates were applied on (10-12%) 
sodium dodecyl sulfate (SDS)–polyacrylamide gel and transferred to a polyvinylidene 
difluoride (PVDF) membrane. Membranes were probed with primary antibodies 
overnight at 4°C. Each primary antibody binding was detected with a horseradish 
peroxidase (HRP)-conjugated secondary antibody and visualized by the enhanced 
chemiluminescence (ECL) method. Band intensity was normalized to the signal 
intensity of internal controls using Image-Pro Plus software. Normal group (positive 
control) (cells were cultured in DMEM+10% FBS, in a 95% O2 atmosphere) n=5; H/SD 
group (negative control) (cells were cultured in simulated ischemia solution, in a 1% 
O2 atmosphere), n=5; and 7Ap + H/SD group (cells were exposed to 1 ng/mL 7Ap and 
cultured in simulated ischemia solution, in a 1% O2 atmosphere), n=5. All experiments 
were replicated 3 times. 
 
2.6 MI model and experimental groups 
For this study, C57/B6 (female, 20 ± 2 g), were purchased from the Laboratory 
Animal Center of the Academy of Military Medical Sciences (Beijing, China). All 
animal experiments were carried out using the guidelines established by the Tianjin 
Committee of Use and Care of Laboratory Animals and the overall project protocols 
were approved by the Animal Ethics Committee of Nankai University. During the 
surgery, the body temperature of the mouse was maintained at 37.5°C ± 0.5 using a 
heating table. During the first 4 days, mice were offered NovaMin sulfone (metamizol) 
(10 drops/300 mL water) for pain-free, and the drinking water was replaced daily. The 
animals’ conditions, such as activity, behavior, lethargy, lack of appetite, and hair 
texture were assessed each day. The mice were euthanized when they exhibited 
significant impairments of their conditions. 
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Mice were randomly assigned to 4 groups as follows: No MI-operation, n = 5; MI-
saline, n = 6; MI-collagen, n = 10; MI-7Ap-collagen, n= 12. 
The MI model was induced by permanent ligation of the left anterior descending 
coronary artery (LAD) as previously described [5]. Briefly, mice were anesthetized 
through inhalation of isoflurane (1–1.5%) in O2, followed by incubation and 
mechanical ventilation using an anesthetic machine (Hallowell EMC MicroVent 1, 
Pittsfield, MA, USA). After the mice entered a relaxed state without breath depression 
and dysphoria, the LAD was permanently ligated using a 7–0 silk suture via a left 
thoracotomy at the fourth intercostal space. Infarction was considered successful 
following the visual appearance of pale discoloration. Two days after injection, mice 
were assessed by Echocardiographic (ECG) and only those exhibiting 38%-45% LV-
EF were included in the study (Supplementary Fig. S1). 
After ligation, 20 μl of 7Ap-collagen, collagen, or saline were administered in two 
injections into two areas adjacent to the infarcted zone with a 30-gauge needle (BD 
Biosciences, USA). Afterward, the chest wall and skin were closed. When the 
anesthesia was stopped, the animals woke up immediately (normally in approximately 
1–2 min). No MI operations were performed on another 5 mice without LAD occlusion. 
2.7 ECG assessment 
Mice were anesthetized through inhalation of isoflurane (1–1.5%) in O2 and ECG 
was performed on mice using a VisualSonics echocardiographic system equipped with 
a 30-MHz transducer (RMV-707B; Toronto, Canada) 2 days and 2 weeks post-MI. The 
motion of the myocardium overtime was recorded using B and M Mode at the level of 
the papillary muscle. The continuous pressure and volume signals were monitored and 
analyzed using the Vevo2100 V3.0.0 Software (VisualSonics Inc., Canada). All 
analyses were performed by a single investigator who was blinded to the treatment 
groups. Heart function indices including LV Stroke Volume, LV Ejection Fraction, and 
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LV Cardiac Output were calculated based on the ECG records. All analyses were 
performed by a single investigator who was blinded to the treatment groups. 
 
2.8 Histologic analysis 
After ECG measurement, mice were euthanized by 5% potassium chloride (KCL) 
perfusion. Overdose of 5% KCL may cause cardiac conduction blockages in the 
diastolic phase. Then, the hearts were isolated, embedded in liquid nitrogen, and cut 
into 5-μm-thick sections. Five consecutive sections at 1-mm intervals were stained with 
Masson’s Trichrome for infarct size, infarct wall thickness, and collagen deposition 
evaluation as reports previously [21, 22]. The infarct size (2 sections/mouse) was 
calculated from sections stained with Masson’s Trichrome. Briefly, the lengths of the 
infarcted surfaces, involving both epicardial and endocardial regions, were measured. 
And the infarct size was determined as a percentage of the total LV circumference. 
Infarct wall thickness (2 Sections/mouse) was derived from an average of 3 
measurements taken throughout the respective regions. To evaluate fibrosis (2 
Sections/mouse), the methyl blue positive regions of collagen deposition were 
examined in 10 randomly chosen fields per section using Image-Pro Plus software. 
Collagen density was expressed as the ratio of collagen deposition to myocardial tissue 
in percentage. All data were analyzed using Image-Pro Plus software (version 6.0; 
Media Cybernetics, Silver Spring, MD, USA).  
2.9 Immunofluorescent and immunohistochemistry evaluation  
Endothelial cells contain von Willebrand factor (vWF) in vesicles in the quiescent 
state, enabling the labeling of endothelial cells. Arterioles usually have one or two 
layers of smooth muscle as muscular walls, thus the alpha-smooth muscle actin (a-SMA) 
can be used for arteriole staining. Isolectin IB4 is a glycoprotein and has particular 
strong affinity for capillaries. In this study, to determine the angiogenic effects of 7Ap, 
frozen sections were immunostained with primary antibodies against vWF (Dako, 
10 
 
Denmark; 1:200 dilution) for vessels (diameter > 50 μm), a-SMA (Boster 
Biotechnology, China; 1:200 dilution) for arterioles (diameter ˂ 50 μm), and isolectin-
IB4 conjugated with Alexa Fluor 488 (Molecular Probes, USA; 1:200 dilution) for 
capillaries. After primary antibody incubation at 4°C overnight, the secondary 
antibodies of goat anti-rabbit Alexa-Fluor 488 or goat anti-rat Alexa-Fluor 488 
(Invitrogen, USA; 2mg/mL, 1:1000 dilution) were incubated with sections for 2 hours. 
To determine stem cell recruitment, frozen sections were immunostained with primary 
antibody against stem cell antigen-1 (Sca-1; Abcam, USA; 1:200 dilution). After 
incubation of primary antibodies overnight at 4°C, the secondary antibodies of rabbit 
anti-mouse Alexa-Fluor 488 (Invitrogen, USA; 2mg/mL, 1:1000 dilution) was 
incubated with sections for 2 h. Meanwhile, to determine the cardiomyocyte 
proliferation, frozen sections were co-immunostained with primary antibody against 
Ki67 (Abcam, USA; 1:200 dilution) and Troponin T (Abcam, USA; 1:200 dilution). 
The secondary antibodies of rabbit anti-mouse Alexa-Fluor 546 (Invitrogen, USA; 
2mg/mL, 1:1000 dilution) and goat anti-rabbit Alexa-Fluor 546 (Invitrogen, USA; 
2mg/mL, 1:1000 dilution) were incubated with sections for 2 hours. The sections 
without incubation with primary antibodies were used as negative controls. The nuclei 
were counter-stained with 4,6-diamidino-2-phenylindole (DAPI) containing mounting 
solution (DAPI Fluoromount G, Southern Biotech, England). The samples of the 
vessels, arterioles, and capillaries, Sca-1+ cells were observed using a fluorescence 
microscope (Zeiss Axio Imager Z1, Germany). The samples of Ki67+/troponin T+ cells 
and Troponin T+ cardiomyocytes were analyzed using LSM 780 confocal microscopy 
(Carl Zeiss). The infarct areas, border zones, and remote areas were defined as reported 
previously [13, 22, 23]. The numbers of vessels, arterioles, and capillaries, Sca-1+ cells, 
Ki67+/troponin T+ cells, and Troponin T+ cardiomyocytes were counted in 10 randomly 
chosen high-power fields (HPF) of the border zone. Results were expressed as cells per 
mm2. All morphometric studies were performed by 2 examiners who were blinded to 
the treatment. 
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TUNEL staining of frozen embedded tissue of all the experimental groups was 
performed by using a TUNEL apoptosis assay kit (Beyotime Biotechnology, China). 
For each slide, 5 separated fields were randomly selected, and cells with clear nuclear 
labeling were defined as TUNEL-positive cells. The apoptotic index was calculated as 
the number of TUNEL-positive cells at the border zone of infarct area. Images were 
observed under an inverted microscope (Nikon Eclipse TE2000-U Kanagawa, Japan).  
2.10 Statistical analysis 
All data were presented as means±SEM. An independent t-test was used for two-
group comparisons, and one-way analysis of variance (ANOVA) was used for multiple-
group comparisons, Least significant difference (equal variances) and Dunnett’s T3 
(non-equal variances) post hoc tests were used for testing the differences between 
groups. A p-value of p< 0.05 was considered to be statistically significant.  
3. Results 
3.1 7Ap increased H9C2 cell survival under hypoxia and serum deprivation (H/SD) 
MI induces hypoxia and blood supply in the infarcted area, causing cardiomyocyte 
apoptosis. To test whether 7Ap could increase cardiomyocyte survival, we first 
assessed its effect on H/SD-induced apoptosis in vitro with the rat cardiac myoblast cell 
line H9C2. As shown in Fig.s 1A and 1B, H/SD-induced apoptosis in H9C2 cells, which 
was significantly reduced by the presence of 7Ap, as revealed by FACS analysis. 
Further experiments with western blot analysis demonstrated that 7Ap treatment 
increased Bcl2 and Akt phosphorylation but decreased cytochrome C (Fig. 1C), which 
may contribute to the 7Ap-mediated cell survival protection.  
3.2 Characterization of 7Ap-7Ap-loaded collagen hydrogel 
Hydrogel containing bio-therapeutic materials, such as peptides, have been widely 
used in MI therapy [24]. In this study, 7Ap was physically incorporated into the 
hydrogel (Fig.s 2A-D). Because of the thermo-sensitive properties of the collagen, the 
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higher temperature resulted in its faster gelation (Fig.s 2A and 2B). It took 7.51 min to 
form hydrogel at 37°C. Moreover, the morphologic structure of 7Ap-collagen was 
examined by scanning electron microscopy (Fig. 2C). Additionally, the representative 
release curve of 7Ap from hydrogel was shown in Fig. 2D. The release rate was rapid 
during the initial 32 h, and cumulative release was 32.0% of the theoretical value, then 
slowed down to a steady rate. The total release of 7Ap reached about 43.5% after 128 
hours and no burst release was observed during the detection period.   
The bioactivity of 7Ap released from collagen hydrogel also evaluated. It still has 
the function of anti-apoptosis after collagen encapsulation (Supplementary Fig. S2).  
3.3 Local delivery of 7Ap via 7Ap-collagen improved LV function following MI 
To test whether 7Ap had therapeutic protection in vivo, MI was introduced in mice 
via LAD ligation. Two injections of 7Ap-collagen were performed on both sides of 
ligated area (Fig. 2E). No MI operation, saline, and collagen were included as controls.  
Meanwhile, the in vivo localization and retention of 7Ap at different time-points were 
analyzed by using FITC-labeled peptides. The peptides remained in the ischemic zone 
for up to 5 days and gradually removed from the heart with the degradation of collagen 
hydrogel (Supplementary Fig. S3). 
Fourteen days post-surgery, LV function was evaluated using ECG. B and M-mode 
echocardiography showed important indicators for blood pumping function, such as 
ejection fraction and cardiac output. In comparison to the no MI group, the infarcted 
mice displayed a decrease in blood pumping function, which was significantly 
improved by the local delivery of 7Ap. As shown in Fig. 3A, 7Ap treatment restored 
LV function significantly. As expected, infarction increased the ratio of heart weight to 
body weight (Fig. 3B) (Values: no-MI, 4.8± 0.1, saline, 5.1 ± 0.2; collagen, 4.9 ± 
0.2; 7Ap-collagen, 4.9 ± 0.1). As reported previously [6], infarction significantly 
decreased LV stroke volume (Fig. 3C) (Values: no-MI, 45 ± 8, saline, 23 ± 3; 
collagen, 25 ±  5; 7Ap-collagen, 38 ±  6), LV fractional shortening (Fig. 3D) 
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(Values: no-MI, 34 ± 3, saline, 21 ± 4; collagen, 21 ± 2; 7Ap-collagen, 30 ± 
5), LV ejection fraction (Fig. 3E) (Values: no-MI, 68 ± 6, saline, 37 ± 5; collagen, 
42 ± 4; 7Ap-collagen, 57 ± 4), and LV cardiac output (Fig. 3F) (Values: no-MI, 22 
±  3, saline, 10 ±  2; collagen, 11 ±  1; 7Ap-collagen, 16 ±  1), which were 
significantly improved by the delivery of 7Ap, indicating a recovery in blood pumping 
and improvement in ventricular filling. We also evaluated the LV end-diastolic diameter 
(LVEDd) and LV end-systolic diameter (LVEDs) of hearts post-MI (Fig.s 3G and H). 
And 7Ap delivery reduced LVEDd significantly (Fig. 3G) (Values: no-MI, 3.8 ± 0.1, 
saline, 4.4 ± 0.4; collagen, 4.0 ± 0.2; 7Ap-collagen, 3.9 ± 0.2), whereas the 
LVEDs was not markedly affected by 7Ap treatment (Fig. 3H) (Values: no-MI, 2.6 ± 
0.3, saline, 3.8 ± 0.5; collagen, 3.5 ± 0.5; 7Ap-collagen, 3.3 ± 0.6). Thus, 7Ap 
treatment significantly enhanced contractility, decreased stiffness, and increased 
elasticity of the LV. 
3.4 Local delivery of 7Ap increased angiogenesis in the infarcted region 
Angiogenesis plays an essential role in heart function recovery following MI. 
Therefore, we assessed new vessel formation to explore whether 7Ap-mediated 
protection occurred through angiogenesis enhancement. Capillaries in the MI border 
region were examined by Isolectin IB4 staining. The capillary density in the 7Ap-
treated hearts was significantly higher than that in the saline and collagen groups at 14 
days (Fig. 4A) (Values: no-MI, 14630 ± 755, saline, 10700 ± 330; collagen, 10501 
± 541; 7Ap-collagen, 12310 ± 752). Indeed, small arterioles (diameter < 50 μm) 
reduced significantly in the ischemic myocardium. Conversely, cardiac arteriole 
density was preserved moderately in the border zone of the LV in the 7Ap-collagen 
group (Fig. 4B) (Values: no-MI, 47 ± 9, saline, 23 ± 8; collagen, 26 ± 12; 7Ap-
collagen, 40 ± 8). Microvascular density in the ischemic myocardium was assessed 
by vWF immunostaining 14 days following 7Ap delivery (Fig. 4C) (Values: no-MI, 6 
±  8, saline, 29 ±  11; collagen, 46 ±  11; 7Ap-collagen, 118 ±  23). In 
comparison to other MI-treated groups, 7Ap increased the vessel density approximately 
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3-fold in the treated hearts. These results suggest that 7Ap treatment could improve the 
angiogenic properties in the post-ischemic heart (Fig.s 4D-F). 
LAD ligation results in MI and causes post-infarction cardiac remodeling, which 
exhibits typical histological changes, including progressive ventricular chamber 
dilation, thinning of the LV wall, and extensive collagen deposition (Fig. 5). We 
calculated the infarct size and LV anterior wall thickness based on 2 Masson’s 
trichrome-stained sections. Although the infarct size did not differ significantly among 
different MI-treated groups, LV infarct wall thickness was significantly increased in 
the 7Ap treated group compared to other MI-treated groups (Fig. 5A). Computerized 
planimetry of heart cross-sections indicated that more collagen deposition occurred in 
all MI-treated groups (Fig. 5B), whereas the 7Ap-collagen group showed markedly 
decreased collagen deposition compared to other MI-treated groups (Fig.s 5C-E). These 
data suggest that 7Ap delivery maintains the LV geometry well and reduces the adverse 
ventricular remodeling. 
3.5 Local delivery of 7Ap inhibited apoptosis, enhanced Sca-1+ stem cell recruitment 
and differentiation, and stimulated cardiomyocyte cycle progression 
Apoptotic effects were evaluated in peptide-treated animals at 14 days post-MI. More 
apoptotic cells (TUNEL positive cells) were observed in MI-treated groups 14 days 
post MI, whereas there were only a few TUNEL-positive cells in the border zone of the 
7Ap-treated hearts, and there was significant difference in TUNEL-positive cells 
between 7Ap and other MI-treated groups (Fig. 6A). These findings suggest that the 
anti-apoptotic effects of 7Ap delivery may be one important mechanism responsible for 
the beneficial cardiac effects. 
Sca-1+ stem cell homing and differentiation after 7Ap injection was evaluated by 
immunohistochemical staining (Fig. 6B). The Sca-1+ stem cell numbers were 
significantly increased in the 7Ap-collagen group compared to the saline and collagen 
groups. Further experiment with double immunofluorescence staining using CD31 (red) 
and Sca1 (green) antibodies (Supplementary Fig. S4) revealed that part of the CD31 
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cells were also Sca1+, indicating Sca-1+ stem cells can differentiate and contribute to 
vascular remodeling following cardiovascular injury. Meanwhile, the delivery of 7Ap 
dramatically increased Ki67+/troponin T+ cell numbers and the ratio of Ki67+/troponin 
T+ cell vs Troponin T+ cardiomyocytes was increased significantly at the border zone 
of MI (Fig.s 7A-C, Supplementary Fig. S5 and Fig. S6). These phenomena reflect that 
7Ap may not only recruit Sca-1+ stem cells into the infarcted area, but also stimulate 
the cardiomyocyte cycle progression, increasing the pool of proliferating 
cardiomyocytes.  
 
4. Discussion 
The major goal of cardiac tissue engineering is to create a favorable 
microenvironment in ischemic regions in order to regenerate the damaged heart tissue 
and preserve the heart function. Stem cells, growth factors, and other bio-activate 
elements have been applied to treat ischemic hearts [25-27]. Numerous 
functional/therapeutic peptides have been widely applied for cardiac disease research 
due to their advantages of easy synthesis, low toxicity, and rapid tissue absorption [24, 
28].  
A therapeutic bio-activate peptide, 7Ap, which is derived from the sORF of Hdac7 
and functions as a phosphate transfer carrier in cellular signal transduction plays a vital 
role in promoting endothelial progenitor cells, especially Sca-1+ stem cell migration 
and self-renewal capacity. Meanwhile, 7Ap may induce capillary vessel network 
formation and promote blood perfusion recovery. In this study, we evaluated its 
potential in tissue repair after MI by incorporating 7Ap peptides into the rat tail-derived 
collagen. 
We have demonstrated that the 7Ap-collagen can promote the micro-vessel 
formation in ischemic areas, thus supporting cellular survival, limiting the degree of 
cardiac fibrosis, preventing the LV negative remodeling, and finally improving heart 
function in the murine MI model. 
In the 7Ap-collagen group, the survival rate of cells was significantly higher 
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compared to collagen and saline groups. Consistently, the in vitro data revealed the 
peptide’s anti-apoptotic function in H9C2 cells. Our results proved that the anti-
apoptotic effects of 7Ap are partly due to its inactivating cytochrome 3 protein, 
activating Bcl-2 protein, and stimulating ERK phosphorylation, which is an important 
component of the MEK-ERK pathway.  
Recent studies have supported the idea that cardiomyocytes in adult mammals can 
be stimulated to re-enter the cell cycle [29, 30]. Meanwhile, our in vivo results 
demonstrated that 7Ap dramatically increased Ki67 protein expression at the border 
zone of MI, which regulates cardiomyocyte transition from the G2 (secondary growth) 
phase to the S phase during cell cycle progress. Cardiomyocyte in S phase enhances 
DNA replication and suggests cells are “primed” for proliferation. At the infarct border 
zone, Ki67 expression may have the potential to increase the pool of proliferating 
cardiomyocytes. 
A higher cellular survival rate and cardiomyocyte cycle progression synergism 
increased LV wall thickness. The benefits of increased LV wall thickness are the altered 
properties of surrounding tissue and decreased LV wall stress. Less LV wall stress 
results in reduced end diastolic volume. The decrease in LV wall stress is also thought 
to protect the vulnerable myocardium, reducing apoptosis and infarct expansion, and 
thus preventing pathologic LV remodeling. 
In addition, the current study has shown that intra-cardiac 7Ap injection may recruit 
the Sca-1+ stem cell migration to the ischemic myocardium. Sca-1+cell population has 
the potential of promoting the neo-vessel formation, modulating the cardiac progenitor 
cell proliferation and further restoring the cardiac function [31, 32]. Furthermore, 
implantable collagen may supply a 3D microenvironment for homing endogenous Sca-
1+ stem cell retention, survival, and differentiation.  
Our research has shown that 7Ap treatment improved the capillary density and 
promoted neovascularization at the border zone of the ischemic heart. In a parallel study 
[12], we have demonstrated that the inclusion of 7A, especially the phosphorylated 
version, 7Ap, significantly increased endothelialization. The majority of the endothelial 
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cells derived from the local resident Sca-1+ stem cells of the surrounding tissues, 
because 7Ap can serve as a chemoattractant for Sca-1+ stem cells and direct their 
differentiation toward the EC lineage. In this study, we proved that the benefit of vessel 
formation around the MI area is associated with the resident Sca-1+ stem cell migration 
and differentiation (Fig. S6). Additionally, increased angiogenesis post-MI indicated 
that 7Ap treatment could be more advantageous in long-term MI therapy if it can sustain 
the degree of mature vasculature formation. 
Myocardial fibrosis is a key contributor to cardiac dysfunction after MI. The 
pathological accumulation of fibrosis at the infarcted site might present a physical 
barrier that impairs the migration and repair of stem cells [33]. Fibrosis analysis showed 
that 7Ap delivery significantly decreased the fibrosis size at the border of the infarcted 
zone as compared to other MI-treated groups. The 7Ap has a positive effect on 
vascularization, and reduced extent of fibrosis could be the downstream of this 
beneficial effect, as well as the reconstruction of the LV. 
There are also several limitations in this study. First of all, we only implanted 7Ap 
collagen hydrogel for up to 2 weeks. Long-term evaluation will elucidate its potential 
for the regeneration of infarcted myocardium. In addition, the exact mechanism of 7Ap 
leading to cardiac regeneration in MI has not been investigated in this study. Finally, 
the clinical relevance associated with a mouse MI model is absent. In the clinical setting, 
factors such as the LV volume and structure, biomaterial injection volume, and method 
for injection will be very different from those in the small animal model. 
5. Conclusions 
In summary, we developed and characterized a bioactive 7Ap-loaded collagen 
hydrogel for in situ tissue repair in the settings of MI. In vivo, intra-myocardial delivery 
of 7Ap-loaded collagen in a mouse MI model decreased cellular apoptosis, enhanced 
Sca-1+ stem cell recruitment and differentiation, and increased neovascularization 
formation. As a result, increased infarct wall thickness and improved heart function, 
and finally attenuated adverse cardiac remodeling have been observed for up to 2 weeks. 
This study demonstrates the potential of the implementation of 7Ap for ischemic 
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cardiac tissue repair. Additional studies are needed in order to understand the 
mechanisms underlying the myocardial regeneration stimulated by the 7Ap-loaded 
hydrogel and to further improve their therapeutic efficacy. 
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Figure Legends 
Fig. 1. 7Ap treatment suppressed H/SD-induced apoptosis in H9C2 cells. H9C2 
cardiac myoblasts were treated with or without 1 ng/ml of 7Ap under H/SD conditions 
for 2 h, followed by FACS analysis (A: FACS images and B: quantitative analysis of 
Annexin V-positive cells in each group) and western blot analysis (C, left panel shows 
the western blot images, right panel shows the relative ratio of the target protein to 
GAPDH with that of normal group set as 1.0). Data presented were representative 
images or mean SEM of 3 independent experiments. *: p< 0.05. 
Fig. 2. Preparation and MI injection of 7Ap-loaded collagen hydrogel. (A) 
Quantification of the gelation time of the collagen I hydrogel at different temperatures 
(n = 3 per temperature). (B) The morphology of collagen before and after gelation. (C) 
Scanning electron microscope image of collagen hydrogel. (D) The cumulative release 
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of 7Ap from the collagen hydrogel. (E) MI surgery and the intra-myocardial delivery 
of 7Ap-loaded collagen following MI. After ligation (red cross), 7Ap-collagen was 
administered in two injections (full black arrows) into two areas adjacent to the 
infarcted zone (gray circle), left panel. 
Fig. 3. Intramyocardial delivery of 7Ap-collagen restored cardiac functions 14 
days post-MI. (A) Representative echocardiographic 2D images of hearts of each 
group. (B) heart weight/body weight, (C) LV stroke volume, (D) LV fractional 
shortening, (E) LV ejection fraction, (F) cardiac output, (G) LV dimensions at end-
diastole, (H) LV dimensions at end-systole. *p < 0.05. No MI (n=5), saline (n=6), 
collagen (n=6), 7Ap-collagen (n=7). 
Fig. 4. Intramyocardial delivery of 7Ap-collagen enhanced neo-vascularization 14 
days post-MI. (A) Representative images of isolectin IB 4 (green)-stained capillaries 
at the border zone, (400×). (B) Representative images of αSMA (green)-stained 
arterioles at the border zone (200×). (C) Representative images of vWF (green)-stained 
blood vessels at the border zone (400×). (D) Qualification of capillary, arteriole, and 
blood vessel density at the border zone of ischemic myocardium. Data shown as mean 
SEM; *p < 0.05. No MI (n=5), saline (n=6), collagen (n=6), 7Ap-collagen (n=7). 
Fig. 5. Intramyocardial delivery of 7Ap-collagen alleviated MI progression and 
collagen deposition 14 days post-MI. (A) Representative heart cross-sections stained 
with Masson’s trichrome 14 days post-MI. (B). Representative heart cross-sections 
stained with Masson’s trichrome at the border zone 14 days post-MI. (C) Quantitative 
analysis of infarct size and anterior wall thickness 14 days post-MI. (D) Quantitative 
analysis of collagen deposition at the border area 14 days post-MI. Data shown as mean 
SEM; *p < 0.05. No MI (n=5), saline (n=6), collagen (n=6), 7Ap-collagen (n=7). 
Fig. 6. 7Ap-collagen injection reduced apoptosis and improved Sca-1+ stem cell 
recruitment 14 days post-MI. (A) Representative images of TUNEL-positive nuclei 
(brown dots; white arrows) at the border zone (200×). (B) Representative images of 
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Sca-1+ (green) stem cells at the border zone (400×). (C-D) Quantitative analysis of 
TUNEL-positive nuclei and Sca-1+ stem cells at the border area 14 days post-MI. Data 
shown as mean SEM; *p < 0.05. No MI (n=5), saline (n=6), collagen (n=6), 7Ap-
collagen (n=7). 
Fig. 7. 7Ap-collagen injection activated Ki67+/troponin T+ cell cycle progression 
14 days post-MI. (A) Representative images of Ki67+/troponin T+ cardiomyocytes at 
the border zone (400×). White arrows indicate the Ki67+ nuclei. (B) Quantitative 
analysis of Ki67+/troponin T+ cell at border area 14 days post-MI. (C) Quantitative 
analysis of the ratio of Ki67+/troponin T+ cell vs Troponin T+ cardiomyocytes at border 
area 14 days post-MI. Data shown as mean SEM; *p < 0.05. No MI (n=5), saline (n=6), 
collagen (n=6), 7Ap-collagen (n=7).  
